Previous close | 7.17 |
Open | 7.01 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 6.89 - 7.13 |
52-week range | 2.12 - 14.82 |
Volume | |
Avg. volume | 54,660 |
Market cap | N/A |
Beta (5Y monthly) | 0.06 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.39 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.alti
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA) Title: Focusing on the
GAITHERSBURG, Md., April 25, 2024 (GLOBE NEWSWIRE) -- The Altimmune team would like to express our sorrow and extend our heartfelt condolences to Dr. Stephen Harrison’s family following his tragic and unexpected passing. Dr. Harrison’s countless contributions to advancing needed treatments for metabolic liver disease will leave a profound and lasting legacy throughout our field, with his patients and the people engaged in understanding and treating liver disease. His brilliance and vision were o